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ABSTRACT
Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker 
for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes 
prostate cancer progression, suppression of AR signaling induces chemokine (CC 
motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic 
potential. AR-controlled PSA alone may be an unreliable biomarker for patients 
receiving androgen deprivation therapy. Therefore, we investigated the validity of 
CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach 
of enriching for prostate cancer cells with higher migration potential showed that 
CCL2 activated cellular migration. Importantly, we found that CCL2 levels were 
significantly different between men (n = 379) with and without prostate cancer. 
Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer 
-specific survival than those with CCL2 < 320 pg/mL. A novel risk classification was 
developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and 
scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, 
and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker 
for prostate cancer. The novel risk classification based on combining CCL2 and PSA 
is more reliable than using either alone.
INTRODUCTION
Prostate cancer is the most common malignancy and 
the second leading cause of cancer death in males in the 
United States [1]. Because androgen/androgen receptor 
(AR) signaling promotes prostate cancer progression, 
standard treatment for patients with advanced prostate 
cancer employs androgen-deprivation therapy (ADT) 
[2-4]. However, prostate cancer often progresses to 
castration-resistant prostate cancer (CRPC) after several 
years of ADT [5]. Although prostate-specific antigen 
(PSA) is a reliable biomarker for prostate cancer, it has 
significant limitations [6, 7]. We previously showed 
that the suppression of AR signaling not only inhibited 
prostate cancer cell proliferation and PSA secretion 
but also promoted CCL2 secretion, enabling prostate 
cancer cells to metastasize [8]. AR-controlled PSA 
alone lacks reliability as a biomarker, and identification 
of complementary biomarkers to PSA is required for 
accurate prediction. In the present study, we investigated 
the validity of chemokine (CC motif) ligand 2 (CCL2) 




CCL2 induces prostate cancer cell migration in 
vitro
To determine the in vitro effects of CCL2 
stimulation on prostate cancer cell migration without 
androgen deprivation, we used a transwell migration 
assay. We found that CCL2 induced prostate cancer cell 
migration (Figure 1A). Next, we analyzed the levels 
of markers that are often associated with enhancing 
cellular migration in CCL2-treated prostate cancer cells. 
Western blot (WB) analysis showed that CCL2 treatment 
upregulated mesenchymal markers such as Snail, MMP-
9, and pSTAT3 and down-regulated the epithelial marker 
E-cadherin (Figure 1B).
Prostate cancer cells with higher migration 
potential secrete higher levels of CCL2
To enrich the population of prostate cancer cells 
with increased migration potential, we established an in 
vitro transwell model (Figure 2A). After selection, we 
confirmed that the ability of selected prostate cancer cells 
(mig cells) to migrate through the transwell and adhere 
to the lower chamber for growth (Figure 2B, 2C). The 
CCL2 ELISA data showed that autocrine CCL2 levels 
were significantly increased in the selected mig cells 
with increased in vitro migration ability (Figure 3A), 
implicating increased autocrine production of CCL2 by 
prostate cancer cells as a key step in the promotion of 
prostate cancer cell migration. We investigated whether the 
changes in the mRNA levels of two important contributors 
to the epithelial-mesenchymal transition (EMT), AR, and 
transforming growth factor-β1 (TGF-β1), were associated 
with increased autocrine CCL2 levels. In selected mig 
cells with increased CCL2 levels, the increased level 
of TGF-β1 mRNA correlated inversely with that of AR 
(Figure 3B, 3C), suggesting that during CCL2-mediated 
EMT, prostate cancer cells differentially regulated the 
levels of AR and TGF-β1 to enable prostate cancer cells 
to increase their ability to migrate in vitro. WB analysis 
showed an increase in the expression of the mesenchymal 
marker N-cadherin and a decrease in the expression of 
E-cadherin and AR (Figure 3D). These data suggest that 
autocrine production of CCL2 induced prostate cancer 
cell migration in vitro and that in the EMT, regardless of 
the presence or absence of the suppression of androgen/
AR signaling, prostate cancer cells with higher migration 
potential secreted more CCL2 (Figure 3E). Therefore, 
CCL2 may serve as a biomarker for aggressive prostate 
cancer with higher migration ability.
CCL2 as a diagnostic marker
Next, we investigated the clinical relevance of 
increased CCL2 levels to support the findings of the in 
vitro experiments. Four potential serum biomarkers 
were measured in biopsies of 379 men who were 
screened before biopsy using the PSA test, digital rectal 
examination, and transrectal ultrasonography. There 
were 255 and 124 men with and without prostate cancer, 
respectively. The areas under the ROC curves for PSA and 
CCL2 were 0.722 and 0.609, respectively (Supplementary 
Figure S1). However, there was a statistically significant 
difference in CCL2 levels between men with and without 
prostate cancer (p < 0.0001) (Table 1). Scatter plots of 
PSA and CCL2 levels showed that men without prostate 
cancer clustered around a small area of low PSA and 
CCL2 concentrations, while those of patients with prostate 
cancer were widely scattered (Figure 4A). Because the 
highest PSA level of men without prostate cancer was 
40.6 ng/mL, the levels of CCL2 in men with and without 
prostate cancer in specific PSA concentrations ranges were 
compared to determine if the CCL2 level was beneficial 
for assisting the diagnosis of prostate cancer of men with 
the lower PSA range. The level of CCL2 in patients with 
prostate cancer was significantly higher than those without 
prostate cancer in all PSA ranges ( < 41, < 20, < 10, 4-41, 
4-20, and 4-10 ng/mL) (Supplementary Table S1). These 
differences in CCL2 levels between men with and without 
prostate cancer support the potential of serum CCL2 levels 
as a diagnostic biomarker for prostate cancer.
CCL2 as a prognostic biomarker
To determine whether CCL2 served as a prognostic 
biomarker of prostate cancer, the levels of CCL2 were 
analyzed for their association with overall survival 
(OS) and prostate cancer-specific survival (PCaSS) 
in 255 patients. Patients with CCL2 ≥ 320 pg/mL had 
significantly poorer OS (p = 0.0008) (Figure 4B) and 
PCaSS (p = 0.0026) (Figure 4C) than those with CCL2 
< 320 pg/mL. As shown in Supplementary Table S2, 
patients with CCL2 ≥ 320 pg/mL had higher TNM stages 
and Gleason scores (GS) than those with CCL2 < 320 pg/
mL. However, there was not a significant difference in 
PSA levels at diagnosis or in treatment regimens between 
groups. When the prevalence of the CCL2 value was 
analyzed in each stage of TNM and GS, advanced stages 
showed higher CCL2 levels, except for M stage (Figure 
5A-5D). However, the analysis of CCL2 levels revealed 
that patients with a higher CCL2 level had a higher 
prevalence of meastasis (Supplementary Figure S2).
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Figure 1: The effect of CCL2 on human prostate cancer C4-2 cells. A. The migration of C4-2 cells in the absence of suppression 
of androgen/AR signaling was performed using 24-well transwell inserts and plates with or without treatment using the indicated 
concentrations of CCL2. B. WB analyses of mesenchymal markers (MMP9 and Snail), an epithelial marker (E-cadherin), and STAT3 in 
C4-2 cells after treatment with 10 ng/mL of CCL2 were performed and compared with the control. The activation of STAT3 (pSTAT3), 
which is a key molecule bridging between CCL2 and EMT, was associated with the EMT.
Figure 2: The enrichment of the population of prostate cancer cells with increased migration potential. A. We established 
an in vitro transwell approach to select prostate cancer cells with increased migration ability. C4-2 cells that migrated from upper transwell 
inserts to the bottom of lower wells were called mig cells. B. The migration of C4-2 prt and mig cells were compared. C. C4-2 cells attached 
to the bottom surface after migration were counted, and the morphological change of mig cells into a polygonal shape was observed.
Figure 3: Characteristics of prostate cancer cells with increased migration potential. A.CCL2 concentrations in supernatants 
of C4-2 prt and mig cells were measured using an ELISA kit. B. mRNA levels of AR expressed by C4-2 prt and mig cells were analyzed 
using qRT-PCR. C. mRNA levels of TGF-β1 in C4-2 prt and mig cells were analyzed using qRT-PCR. D. WB analyses of N-cadherin 
(mesenchymal marker), E-cadherin (epithelial marker), and AR expression by C4-2 mig cells were performed, and the results were 
compared with those for C4-2 prt cells (mig1 and mig2 were independently collected). E. These data indicate that CCL2 induced the 
migration of prostate cancer cells and the EMT in vitro in the presence or absence of the suppression of androgen/AR signaling and that 
prostate cancer cells with higher metastatic potential secreted more CCL2 (red arrow).
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Table 1: Serum biomarkers in biopsied men
No malignancy PCa p
n 124 255
Median PSA, ng/
mL 6.5 (0.9-40.6) 10.6 (1.5-16702) 0.1167
Median CCL2, pg/
mL 224 (70.5-394) 246 (95.3-749) <0.0001
Median TT, ng/mL 4.4 (0.0-10.7) 4.6 (1.4-11.7) 0.1867
Median TGF-β1, 
ng/mL 28.6 (8.3-48.8) 27.4 (8.8-48.4) 0.7947
PCa = prostate cancer, PSA = prostate-specific antigen, TT = total testosterone, TGF-β1 = transforming growth factor β1. 
Values in parentheses indicate range.
Table 2: PCa patients background according to risk
poor intermediate good p
Total, n 11 53 191
Median age, yr 76 (52-79) 71 (46-86) 69 (50-89) 0.2205
T, n 1 1 6 54
0.0068/ 
< 0.0001†
2 1 23 108
3 3 18 26
4 6 6 3
N, n 0 2 41 185 0.0004/ 
< 0.0001†1 9 12 6
M, n 0 3 41 186
0.0009/< 
0.0001†1b 5 9 3
1c 3 3 2
GS, n 6 0 7 52
0.0027/ 
< 0.0001†
7 0 15 83
8 2 17 34
9 8 10 19
10 1 4 3
Treatment, n cADT§ 11 25 42
0.0032/ 
0.0054†‡
+HDR 0 4 7
+seed 0 1 3
+EBRT 0 4 3
+RP 0 0 2
tADT 0 0 10
+HDR 0 6 41
+seed 0 7 25
+EBRT 0 0 7
+RP 0 1 15
HDR 0 0 2
Seed 0 4 13
RP 0 1 16
AS 0 0 5
PCa = prostate cancer, GS = Gleason score, cADT = continuous androgen-deprivation therapy, HDR = high-dose-rate 
brachytherapy, EBRT = external beam radiotherapy, tADT = temporary ADT, RP = radical prostatectomy, AS = active 
surveillance. †Comparison poor and inermediate/ comparison intermediate and good. ‡Treatments are divided into 3 
groups; ADT alone, ADT+local therapy, and local therapy alone. §One hundred were combined androgen blockade and 2 
were monotherapy.
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CCL2 as a predictive biomarker
Of the 255 patients, 102 underwent continuous 
ADT at the time of the latest follow-up, and their CCL2 
concentrations ( ≥ 320 pg/mL) correlated significantly 
with poor OS (p = 0.0104) (Supplementary Figure 
S3A) and PCaSS (p = 0.0372) (Supplementary Figure 
S3B) compared with those with CCL2 < 320 pg/mL. 
Interestingly, patients with CCL2 ≥ 320 pg/mL (10/27, 
37%) had a significantly higher risk of developing CRPC 
than those with CCL2 < 320 pg/mL (11/75, 15%) (p = 
0.0196) (Figure 4D). These results indicate that CCL2 
may serve as a biomarker that predicts the efficacy of ADT 
for prostate cancer.
Novel risk classification combining CCL2 and 
PSA
Consistent with the observations of a previous study 
[9], patients with PSA ≥ 100 ng/mL had significantly 
poorer OS and PCaSS than those with PSA < 100 ng/
mL (Supplementary Figure S4A, S4B). Similarly, in 
patients treated with ADT, PSA > 100 ng/mL correlated 
with poor OS, PCaSS, and CRPC-free survival (CFS) 
(Supplementary Figure S5A-S5C). As shown in 
Supplementary Table S3, patients with PSA ≥ 100 ng/mL 
had higher TNM stages and GS than those with PSA < 100 
ng/mL. Because CCL2 and PSA levels did not correlate, 
we reasoned that these two useful biomarkers might be 
Figure 4: Analysis of PSA and CCL2 levels as functions of OS, PCaSS, and CFS. A. The scatter plot of PSA (logarithmic 
scale) and CCL2 levels shows clustering of patients without prostate cancer around small areas of low PSA and CCL2 levels, and their 
levels in prostate cancer patients were widely scattered. PCa = prostate cancer. B., C. Kaplan-Meier curves of OS and PCaSS in 255 patients 
with prostate cancer with CCL2 ≥ 320 pg/mL and CCL2 < 320 pg/mL. The 5-year OS rates of patients with CCL2 ≥ 320 pg/mL and CCL2 < 
320 pg/mL were 76.9% and 93.9%, respectively. The 5-year PCaSS rates of patients with CCL2 ≥ 320 pg/mL and CCL2 < 320 pg/mL were 
84.3% and 97.3%, respectively. D. Kaplan-Meier curves of the CRPC-free survival (CFS) of 102 patients treated with ADT and patients 
with CCL2 ≥ 320 pg/mL and < 320 pg/mL. The 5-year CFS rates of patients with CCL2 ≥ 320 pg/mL and < 320 pg/mL were 49.5% and 
80.9%, respectively.
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a more powerful biomarker profile for prostate cancer 
when they were combined. The risk classification was 
generated according to the number of risk factors (CCL2 
≥ 320 pg/mL and PSA ≥ 100 ng/mL), and scores of 2, 
1, and 0 were defined as poor, intermediate, and good 
risk, respectively. There were significant differences in 
OS (p < 0.0001) (Figure 6A) and PCaSS (p < 0.0001) 
(Figure 6B) overall among poor, intermediate, and good 
risk groups. There were significant differences in OS (p < 
0.0001, Supplementary Figure S6A), PCaSS (p < 0.0001) 
(Supplementary Figure S6B), and CFS (p < 0.0001) 
(Figure 6C) among the patients from poor, intermediate, 
and good risk groups treated with ADT. As shown in Table 
2, the risk classification divided prostate cancer patients 
into three groups that showed significant differences in 
TNM stages and GS. Moreover, this risk classification 
clearly distinguished each survival risk compared with the 
use of a single biomarker.
DISCUSSION
Human CCL2 was identified in 1987 [10, 11]. 
Originally, CCL2 was reported as a chemical mediator 
attracting mononuclear cells to inflammatory tissue [11, 
12]. Since Loberg et al. reported the detailed mechanism 
of prostate cancer progression via CCL2 [13, 14], the role 
of CCL2 in cancer progression was consistently shown 
in a variety of malignancies [15-17]. Initially, CCL2 was 
reported to promote prostate cancer metastasis through 
the recruitment of macrophages using PC-3 cells that did 
not express AR [18]. We further investigated molecular 
mechanisms by which AR inhibits CCL2 secretion in AR-
positive human prostate cancer cell lines [8, 19]. CCL2 
is secreted by prostate cancer cells and tumor-associated 
macrophages (TAM) during coculture conditions that 
mimic ADT and induces prostate cancer cell migration/
invasion via CCL2-dependent STAT3 activation and the 
EMT pathways [8, 19]. Immunohistochemical analysis 
of tissue specimens suggests that patients with prostate 
Figure 5: The prevalence of CCL2 values in each stage of TNM and GS. A. The levels of CCL2 in patients with each T stage 
were analyzed. The level of CCL2 in patients with T4 was higher than those with T1. B. The levels of CCL2 in patients with each N stage 
were analyzed. The level of CCL2 in patients with N1 was higher than those with N0. C. The levels of CCL2 in patients with each M stage 
were analyzed. There was no significant difference in CCL2 levels between patients with M1 and M0 (p = 0.1277). D. The levels of CCL2 
in patients with each GS were analyzed. The level of CCL2 in patients with GS ≥ 9 was higher than those with GS = 6.
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cancer with high CCL2 expression in their tumors 
had worse OS and shorter time to recurrence after 
prostatectomy than those with low CCL2 expression [8]. 
Further, CCL2 induces resistance to anti-androgens via 
interaction between prostate cancer cells and TAM [8]. 
These results strongly support the potential of CCL2 as a 
biomarker of prostate cancer. However, it remains unclear 
whether CCL2 promotes prostate cancer progression in 
prostate cancer cells regardless of therapeutic targeting 
of androgen/AR signaling. Our present data indicate that 
CCL2 induces prostate cancer cell migration in vitro 
not only under ADT conditions but also without the 
suppression of androgen/AR signaling (Figure 1A, 1B). 
Furthermore, prostate cancer cells with higher migration 
potential secrete more CCL2 (Figure 3A). Therefore, 
CCL2 may serve as a biomarker from the time prostate 
cancer is diagnosed.
TGF-β1 is an EMT marker and promotes prostate 
cancer progression [20, 21] (Figure 3C). Higher serum 
TGF-β1 levels predict biochemical recurrence after 
prostatectomy [22]. Serum testosterone is a prognostic 
prostate cancer biomarker [23]. However, our present 
study shows a significant difference in CCL2 levels 
alone between men with and without prostate cancer. 
Interestingly, this result is consistent with a recent pilot 
study of potential biomarkers for prostate cancer showing 
that CCL2 alone may serve as a diagnostic serum 
biomarker among six chemokines [24]. Double screening 
using serum PSA and CCL2 may reduce unnecessary 
biopsies and facilitate more accurate diagnosis of prostate 
cancer.
Moreover, CCL2 may serve as a prognosticator for 
prostate cancer patients regardless of their disease status 
(Figure 4B, 4C). CCL2 may serve as well as a predictive 
biomarker for patients with prostate cancer treated with 
ADT (Figure 4D), suggesting that ADT alone might 
not be sufficient for patients with prostate cancer with 
higher CCL2 levels. Recent studies demonstrated the 
Figure 6: The novel risk classification. The classification system was designed according to the number of risk factors (CCL2 ≥ 320 
pg/mL and PSA ≥ 100 ng/mL) and 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively. A., B.) Kaplan-Meier curves 
of OS and PCaSS in 255 patients with prostate cancer with poor, intermediate, and good risk. The 5-year OS rates were 52.6%, 83.8%, and 
95.6% of patients with poor, intermediate, and good risk, respectively. The 5-year PCaSS rates of patients with poor, intermediate, and good 
risk were 61.4%, 87.2%, and 99.5%, respectively. C. Kaplan-Meier curves of CFS of 102 patients with prostate cancer treated with ADT. 
The 5-year CFS rates of patients with poor, intermediate, and good risk were 0%, 66.5%, and 93.0%, respectively.
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efficacy of combination therapy with ADT and cytotoxic 
chemotherapy as first-line treatment, particularly for 
selected high-risk patients [25]. Our present data support 
the conclusion that CCL2 status may help clinicians to 
select such patients. Interestingly, chemotherapy resistance 
mediated by CCL2 was reported, and inhibition of CCL2 
activity was suggested to enhance therapeutic responses to 
taxane-based chemotherapy [26].
In addition to the absence of a strong correlation 
between PSA and CCL2 in patients with prostate cancer 
(Figure 4A), we demonstrated the limitation of PSA alone 
as a biomarker for prostate cancer [6, 7, 27]. Furthermore, 
mutually exclusive characteristics are observed between 
activation of androgen/AR signaling and CCL2 secretion 
[8]. Therefore, it is reasonable to combine PSA and CCL2 
as biomarkers to improve the prediction of prognosis of 
patients with prostate cancer. As we expected, our study 
aiming to develop a novel risk classification showed that 
combining PSA and CCL2 predicted OS, PCaSS, and 
CFS of all patients with prostate cancer and those treated 
with ADT compared with PSA or CCL2 alone (Figure 6). 
Because PSA and CCL2 are secreted proteins present in 
blood, the assays of these two proteins are very easy to 
perform and are relatively inexpensive and less invasive.
One may raise the question that the small sample 
size in the present study prevented the determination 
of statistical significance of differences between the 
groups. We believe that larger prospective studies that 
include patients with diverse ethnic backgrounds and 
longer follow-up periods are required to confirm our 
findings. Because patients in the present study were 
screened for PSA before biopsy, it is unclear whether 
CCL2 with or without PSA will serve as a reliable 
biomarker for initial screening. Moreover, treatment with 
recently developed anti- prostate cancer agents such as 
abiraterone, enzalutamide, and cabazitaxel prolong the 
survival of patients with prostate cancer [28]. It remains 
to be determined if changes in CCL2 levels as well as 
any association of this change with the PSA level will be 
detected in patients with prostate cancer before or after 
receiving such therapy. The concentration of CCL2 used in 
migration assay (Figure 1A) was higher than that obtained 
from medium of mig cells (Figure 3A) and serum CCL2 
concentration. We cannot rule out the possibility that mig 
cells may consume CCL2 for cell survival. Similarly, 
systemic CCL2 concentration may be diluted from 
systemic circulation after released from prostate tissue. 
Therefore, we think the concentration of CCL2 used in 
migration assay may be reasonable as the concentration 
in prostate tissue since previous studies have used similar 
concentration of CCL2 for migration assay [29, 30].
CONCLUSION
To our knowledge, the present study is the first to 
investigate serum CCL2 levels using a cohort of prostate 
cancer samples with supporting data from in vitro models 
that reveals the predictive value of serum CCL2 levels as 
a biomarker of prostate cancer. The novel classification 
using CCL2 and PSA levels together may serve as a useful 
tool to improve prediction of survival and the efficacy of 
ADT in patients with prostate cancer.
MATERIALS AND METHODS
In vitro experiments
C4-2 cells were maintained in RPMI-1640 
medium with 5% fetal bovine serum and 1% penicillin/
streptomycin in a humidified 5% CO2 environment at 
37°C. For WB analysis, cells were lysed in RIPA buffer 
(50 mM Tris-HCl/pH 7.4, 1% NP-40, 150 mM NaCl, 
1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF, 
1 mM okadaic acid, and 1 mg/ml aprotinin, leupeptin 
and pepstatin). Individual samples (15 μg-30 μg protein) 
were prepared for electrophoresis through an 8%-12% 
gradient SDS/PAGE gel and then transferred onto PVDF 
membranes (Millipore). After blocking the membranes 
with 5% fat-free milk in TBST (50 mM Tris, pH 7.5, 
containing 0.15 M NaCl and 0.05% Tween-20) for 1 h 
at room temperature, the membrane was incubated with 
appropriate dilutions of specific primary antibodies 
overnight at 4°C. After washing, the blots were incubated 
with anti-rabbit, anti-mouse, or anti-goat IgG horseradish 
peroxidases for 1 h. The blots were developed in ECL 
mixture (Thermo Fisher Scientific). Anti-tubulin, anti-
GAPDH, and anti-AR antibodies were purchased from 
Santa Cruz Biotechnology, Inc. The anti-E-cadherin 
antibody was from R&D Systems. Anti-tSTAT3 and 
anti-pSTAT3 were from Cell Signaling Technology. Anti-
MMP9, anti-Snail, and anti-N-cadherin antibodies were 
from Abcam. Human recombinant CCL2 was obtained 
from R&D systems.
For cell migration assays, 24-well transwell inserts 
were used according to the manufacturer’s instructions, 
and C4-2 cells (105 cells per well) were seeded in the 
upper chamber. Cells were incubated for 24 h. We stained 
cells that migrated to the lower part of the membrane and 
counted six random fields. The culture supernatant was 
used for detection of CCL2 using a human CCL2 ELISA 
kit (R&D Systems) according to the manufacturer’s 
instructions.
For quantitative real-time PCR analysis (qRT-
PCR), total RNA was isolated using Trizol reagent 
(Invitrogen) according to the manufacturer’s instructions. 
One microgram of total RNA was subjected to reverse 
transcription using Superscript III transcriptase 
(Invitrogen). Primers used were as follows: AR forward, 
5′-TATCCTGGTGGAGTTGTG-3′ and AR reverse, 
5′-CAGAGTCATCCCTGCTTC-3′; TGF-β1 forward, 
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5′-TGCTAATGGTGGAAACCCAC-3′ and TGF-β1 
reverse, 5′-ATCGCCAGGAATTGTTGCTG-3′; β-actin 
forward, 5′-TGTGCCCATCTAGGAGGGGTATGC-3′ 
and β-actin reverse, 
5′-GGTACATGGTGGTGGCGCCAGACA-3′. qRT-PCR 
was conducted using a Bio-Rad CFX96 system with 
SYBR green to determine the level of mRNA expression 
of a gene of interest. Expression levels were normalized to 
that of β-actin RNA.
Patients
Serum samples were obtained from men who 
underwent prostate biopsy at Kanazawa University 
Hospital between 2007 and 2013. We performed 10-core 
needle transrectal ultrasound-guided biopsy of the prostate 
gland using an 18 G needle, and samples were obtained 
from the apex, middle, base, and two outer lateral areas 
of bilateral peripheral zones (Supplementary Figure S7). 
Serum values of each biomarker were measured using 
commercially available kits according to the suppliers’ 
instruction manuals: PSA (Beckman Coulter), CCL2 
(R&D Systems), total testosterone (Roche), and TGF-β1 
(R&D systems). Patient characteristics and survival 
data were obtained from their charts and retrospectively 
compared between patients with and without prostate 
cancer and compared among groups divided by each 
cutoff value of each biomarker. Studies were performed 
after receiving approval from the Institutional Review 
Board of Kanazawa University.
Definitions
ADT includes surgical castration, monotherapy 
using a luteinizing hormone-releasing hormone (LH-RH) 
analog or antagonist, and combined therapy using anti-
androgens and an LH-RH analog or antagonist. CRPC 
was defined as the status of at least three consecutive 
elevations of PSA level or a change of antiandrogen 
because of disease progression.
Statistical analysis
The Kaplan-Meier method was used to display 
survival data. We determined p values using paired and 
unpaired Student t tests and Fisher’s exact test, chi-square 
test for trends, the log-rank test to determine survival 
distributions, and p  < 0.05 was considered statistically 
significant. Analyses were performed using Prism 5 
Software (GraphPad).
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